3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Agnosia
1
Interventions
Oxaliplatin
7
Fluorouracil
7
Paclitaxel
5
Leucovorin
5
pembrolizumab
4
Trastuzumab
4
Radiation
4
Capecitabine
4
tislelizumab
3
Taxes
3
Specimen Handling
3
Nivolumab
3
Carboplatin
3
ulixertinib
2
trastuzumab biosimilar HLX02
2
patritumab deruxtecan
2
Surgical Procedures, Operative
2
Radiotherapy
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Irinotecan
2
Exercise
2
Docetaxel
2
Cisplatin
2
CT-P6
2
zolbetuximab
1
zimberelimab
1
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Acetaminophen
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled